Jeanna marta miller12/8/2023 ![]() ![]() Dr Fecher reported grants for clinical trial funding to institution from BMS, Kartos, Array-Pfizer, and EMD/Serono-Pfizer personal fees from Elsevier, study funding from Array-Pfizer ECOG-ACRIN, and funding grants to institution from Merck-Incyte outside the submitted work. Dr Eton reported grants from BMS outside the submitted work. Dr Elkrief reported grants from the Canadian Institute of Health Research outside the submitted work. Dr Bilen reported personal fees from Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi advisory board and grants from Merck, Xencor, Bayer, Bristol Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and a grant to institution from Pfizer outside the submitted work. ![]() Dr Berg reported speakers bureau fees from Eisai, Exelexis, and Bristol Meyers Squibb outside the submitted work. Dr Bashir reported research funding to institution from Amgen, Artios Pharmaceuticals Bicycle Therapeutics, Boehringer Ingelheim, Daiichi Snakyo, KAHR, Merck, Pionyr Immunotherapeutics, RASCAL Therapeutics, Syros Pharmaceuticals,and Tarveda Therapeutics. Dr Gulati reported support to institution for a clinical trial from AstraZenca and Isoray, and personal fees from EMD Serono for advisory board roles outside the submitted work. Dr Labaki reported grants from Genentech/imCORE outside the submitted work. This cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm.Ĭ Identifier: NCT04354701.Ĭonflict of Interest Disclosures: Dr Bakouny reported nonfinancial support from Bristol Myers Squibb, grants from Genentech/imCORE, and personal fees from UpToDate outside the submitted work. Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32 95% CI, 1.42-3.79). Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio, 0.80 95% CI, 0.56-1.13, and aOR, 0.89 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33 95% CI, 1.38-8.01, and aOR, 4.41 95% CI, 1.71-11.38, respectively). A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. The median age of the entire cohort was 65 years (interquartile range, 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. The secondary outcome was the occurrence of cytokine storm. ![]() The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications hospitalized without requiring oxygen hospitalized and required oxygen intensive care unit admission and/or mechanical ventilation death. Immunosuppression due to therapy systemic anticancer therapy (IO or non-IO). Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer. Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |